No doubt the shares are priced at a premium (as they almost always are), but it is very hard to argue against CSL as a "forever" investment.
CSL possible pull back to low $200's, page-32
-
-
- There are more pages in this discussion • 551 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.56 |
Change
0.000(0.00%) |
Mkt cap ! $149.1B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 113 | $331.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$277.67 | 25 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 113 | 331.560 |
1 | 58 | 323.990 |
15 | 3411 | 323.980 |
2 | 560 | 323.670 |
2 | 1507 | 320.670 |
Price($) | Vol. | No. |
---|---|---|
277.670 | 25 | 1 |
277.680 | 98 | 3 |
277.710 | 420 | 1 |
289.890 | 96 | 3 |
290.000 | 651 | 2 |
Last trade - 09.56am 16/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online